摘要
用枸杞多糖（ＬｙｃｉｕｍＢａｒｂａｒｕｍＰｏｌｙｓａｃｃｈａｒｉｄｅｓ，ＬＢＰ）联合ＬＡＫ／ＩＬ－２疗法临床试验治疗７９例晚期肿瘤患者，其中７５例可评估病人资料分析提示，ＬＢＰ联合ＬＡＫ／ＩＬ－２疗法组疗效（４０．９％）显著优于ＬＡＫ／ＩＬ－２疗法组（１６．１％）。两种治疗方案对恶性黑色素瘤、肾癌、直结肠癌、肺癌、恶性胸水和鼻咽癌有一定的疗效。ＬＢＰ联合ＬＡＫ／ＩＬ－２治疗组的缓解持续时间显著长于ＬＡＫ／ＩＬ－２治疗组。ＬＢＰ联合ＬＡＫ／ＩＬ－２治疗组治疗前后外周血淋巴细胞（ＰＢＬ）的ＮＫ、ＬＡＫ活性增高程度均显著大于ＬＡＫ／ＩＬ－２治疗组，说明ＬＢＰ能够提高ＬＡＫ／ＩＬ－２疗法对晚期肿瘤的治疗效果。
Abstract Seventy nine advanced cancer patients in a clinical
trial were treated with LAK/IL-2combining with Lycium Barbarum polysaccharides (LBP).Initial
results of the treatment from 75evaluable patients indicated that objective regression of cancer
was achieved in patients with malig-nant melanoma,renal cell carcinoma,colorectal
carcinoma,lung cancer,nasopharyngeal carcinoma,maligmant hydrothorax.The response rate of
patients treated with LAK/IL-2 plus LBP was 40.9% while that of patients treated with LAK/IL-2
was 16.1%(P<0.05).The mean remission inpatients treated with LAK/IL-2 plus LBP also lasted
significanty longer.LAK/IL-2 plus LBPtreatment led to more marked increase in NK and LAK cell
activity than LAK/IL-2 without LBP.The results indicate that LBP can be used as an adjuvant in
the biotherapy of cancer.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1994年第6期428-431,共4页
Chinese Journal of Oncology
